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Abstract
Background. Increased aldosterone concentrations and
volume expansion of normal pregnancies are hallmarks of
normal pregnancies and blunted in pre-eclampsia. Accord-
ingly, we hypothesized an active mineralocorticoid system
to protect from pre-eclampsia.
Methods. In pregnant women (normotensive n = 44; pre-
eclamptic n = 48), blood pressure, urinary tetrahydro-
aldosterone excretion and activating polymorphisms
(SF-1 site and intron 2) of the aldosterone synthase gene
(CYP11B2) were determined; 185 non-pregnant normoten-
sive individuals served as control. Amino acid-changing
polymorphisms of the DNA- and agonist-binding regions
of the mineralocorticoid receptor were evaluated by RT-
PCR, SSCP and sequencing.
Results. Urinary tetrahydro-aldosterone excretion was re-
duced in pre-eclampsia as compared to normal pregnancy
(P < 0.05). It inversely correlated with blood pressure
(r = 0.99, P < 0.04). Homozygosity for activating
CYP11B2 polymorphisms was preferably present in nor-
motensive as compared to pre-eclamptic pregnancies, iden-
tified (intron 2, P = 0.005; SF-1 site, P = 0.016). Two
mutant haplotypes decreased the risk of developing pre-
eclampsia (RR 0.16; CI 0.05–0.54; P < 0.001). In con-
trast, intron 2 wild type predisposed to pre-eclampsia (P <
0.0015). No functional mineralocorticoid receptor mutant
has been observed.
Conclusions. High aldosterone availability is associated
with lower maternal blood pressure. In line with this obser-
vation, gain-of-function variants of the CYP11B2 reduce
the risk of developing pre-eclampsia. Mutants of the miner-
alocorticoid receptor cannot explain the frequent syndrome
of pre-eclampsia.
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Introduction
Pre-eclampsia (PE), as defined by maternal arterial hy-
pertension and proteinuria in pregnancy beyond the 20th
week of gestation, causes severe morbidity often in pre-
viously healthy individuals [1]. In addition to the imme-
diate effects of the disease that may include cerebral ac-
cidents, liver disease and renal failure, PE is associated
with remote cardiovascular and metabolic disease [2,3].
Thus, the ability to predict PE, especially with tests based
on pathophysiological mechanisms, would be an impor-
tant step towards eventually preventing and managing the
disease.
Extracellular and plasma volume expansion of normal
pregnancy is linked to changes in renal haemodynamics and
of circulating levels of several steroid hormones including
markedly increased circulating aldosterone concentrations
[4–10]. Following production by the enzyme aldosterone
synthase (CYP11B2), aldosterone acts in target tissues via
the mineralocorticoid receptor (MR).
Catalyzed by CYP11B2, aldosterone is synthesized from
deoxycorticosterone in a three-step reaction with 18-methyl
oxidation being rate limiting. In a group of pre-eclamptic
women, we recently observed a reduced CYP11B2 ac-
tivity characterized by a compromised 18-methyl oxi-
dase step due to a loss-of-function mutation of CYP11B2
[11].
In non-pregnant subjects, essential hypertension with
a high aldosterone-to-renin ratio, suggesting a high ac-
tivity of CYP11B2, has previously been attributed to
gain-of-function mutants representing biallelic gene poly-
morphisms of the CYP11B2. This is a -344C/T exchange
located in the putative steroidogenic binding factor-1 (SF-
1) within the 5′ regulatory region and an intron 2 conver-
sion [Int2 (c)] resulting from the replacement of this region
with that of the neighbouring gene encoding CYP11B1
[12].
With respect to our initial finding of an increased preva-
lence of loss-of-function mutants of CYP11B2 in PE, such
gain-of-function alleles might protect from developing PE.
Several functional relevant mutants of the aldosterone ef-
fector, the MR, are known to lead either to a loss or to
a gain of function, which could as such further affect the
aldosterone response [13].
We hypothesized that in pregnancy, gain-of-function
mutants of the CYP11B2 gene in the absence of
loss-of-function polymorphisms of the MR sustain a lower
blood pressure and reduce the risk of developing PE.
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Table 1. Characteristics of the pregnant women studied
Type of pregnancy Normotensive P < Pre-eclampsia
Information from present
pregnancy
N 44 48
Age (years) 33.2 ± 1.3 n.s. 31.2 ± 0.7
BMI
At delivery (kg/m2) 27.4 ± 0.9 n.s. 29.0 ± 0.9
Before pregnancy (kg/m2) 23.0 ± 0.8 0.04 26.3 ± 1.3
Blood pressure
Systolic (mmHg) 117 ± 3 0.001 159 ± 16
Diastolic (mmHg) 75 ± 2 0.001 97 ± 2
Fetal birth weight (g) 3286 ± 98 0.001 1774 ± 179
Birth weight percentiles
corrected for gestation
42.3 ± 4.8 0.01 26.2 ± 4.1
Low birth weight <2.5 kg (%) 7 0.0001 79
SGA <10th birth weight
percentile (%)
21 0.04 42
Gestation at time of sampling
(days)
221.9 ± 9.1 n.s. 224.7 ± 4.9
Proteinuria (g/day) n.d. 0.002 2.3 ± 0.5
Time to delivery (day) 44 ± 6 0.001 6 ± 4
Information from previous
pregnancies
Total number of pregnancies
(n/woman)
1.8 ± 0.2 n.s. 1.8 ± 0.2
Primiparous (%) 53 n.s. 57
Multiparous (%) 47 n.s. 43
History of pre-eclampsia (%) 0 0.001 22
History of HELLP syndrome
(%)
0 n.s. 4
Fetal loss (n/woman) 0 0.02 0.4 ± 0.1
Premature birth (n/woman) 0 0.001 1.1 ± 0.1
Normal birth weight
(n/woman)
1.8 ± 0.2 0.001 0.4 ± 0.1
n.d. = not detectable on either dipstick urinalysis or quantitative assess-
ment of proteinuria, n.s. = not significant, SGA = small for gestational
age.
Material and methods
Patients
Ninety-two pregnant women, 44 with normal pregnancies and 48 with PE,
and 185 normotensive control subjects (115 males and 70 females) were
investigated. Approval by the appropriate hospital ethics review commit-
tee and informed consent were obtained from all individuals. Basic demo-
graphic data, including blood pressure, information on concurrent diseases
and the present medication, were obtained. Women with pre-existing ar-
terial hypertension, diabetes mellitus or renal disease were excluded from
the study. Patients were included in the PE group if blood pressure was
≥140/90 mmHg and proteinuria > 0.3 g/day in the absence of urinary
tract infection beyond the 20th week of gestation (Table 1) [14]. Healthy
pregnant women were selected as case controls according to the gesta-
tional age at initial presentation of pre-eclamptic women. Both groups of
women were followed to delivery.
Collection of urine and blood samples and isolation of genomic DNA
Twenty-four-hour urine samples were collected from all women with PE
at initial presentation. These samples were matched with those from
women with a normal pregnancy at the same gestational age (± 2
weeks); however, analysis was postponed until delivery in order to es-
tablish the presence of an uncomplicated pregnancy. Ten millilitres of
blood samples were drawn into tubes containing EDTA, mixed and
stored at 4◦C. Genomic DNA was extracted from peripheral blood leu-
cocytes following the protocol supplied by the nucleon BACC3 kit
(Bioscience; Piscataway, USA). Purified DNA was stored at 4◦C in
ddH2O.
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Fig. 1. Schematic representation of the human mineralocorticoid receptor
(MR) (A) and aldosterone synthase (CYP11B2) (B) gene. Boxes repre-
sent exon, straight lines intron and dashed lines the 5′ promoter regions.
Mutations are depicted in the frame.
Gas chromatography–mass spectrometry (GC-MS) of
tetrahydro-aldosterone
Urinary tetrahydro-aldosterone was analysed by GC-MS according to the
method described by Shackleton [15]. Sample preparation consisted of
pre-extraction, enzymatic hydrolysis, extraction from the hydrolysis mix-
ture, derivatization and gel filtration. Medroxyprogesterone (2.5 µg) was
added as recovery standard to 1.5 ml urine. The sample was extracted on a
Sep Pak C18 column, dried, reconstituted in a 0.1 M acetate buffer (pH 4.6)
and hydrolyzed with powdered Helix pomatia enzyme (12.5 mg) and 12.5
µl of β-glucuronidase/arylsulfatase liquid enzyme at 55◦C for 3 h. The re-
sulting free steroids were extracted on a Sep Pak C18 cartridge, and a stan-
dard mixture (5α-androstane-3α-17α-diol, stigamsterol and cholesteryl
butyrate, 2.5 µg of each and 0.15 µg of 3β5β-tetrahydro-aldosterone) was
added. The sample was derivatized to form the methyloxime-trimethylsilyl
ethers and gel filtration on a Lipidex 5000 column added. Samples were
analysed on a Hewlett Packard gas chromatograph 6890 equipped with the
mass selective detector 5973 and the auto injector 7683 by selective ion
monitoring for each measured compound against a known calibration stan-
dard (3β5β-tetrahydro-aldosterone against 3α5β-tetrahydro-aldosterone).
Ions were chosen with respect to their retention time during a temperature-
programmed 35-min run (210–265◦C). The urinary concentration of
3α5β-tetrahydro-aldosterone was normalized against urinary creatinine
excretion.
Screening of genomic DNA for the gain-of-function mutants of CYP11B2
[SF-1–344C/T and Int2 (w)/(c)] and functionally relevant mutants of the
MR (Figure 1)
Polymerase chain reaction (PCR) for SF-1 and Int2 polymorphisms of
CYP11B2 was performed using the primers and conditions reported
by Davies et al. [16]. The region of DNA containing the HaeIII/SF-1
polymorphism was amplified by PCR by use of conditions similar to
those previously described. A PCR product of 228 bp was amplified.
This was digested with HaeIII and subjected to electrophoresis in 3%
MetaPhor agarose. The 228 bp amplicon contains two HaeIII restriction
enzyme sites (GG CC). The presence of a C–T transition at position
-344 (GG CT) removes one of these sites. After digestion, individu-
als homozygous for the transition (TT) produce two bands of 175 and
53 bp, individuals homozygous for the wild-type (CC) three bands of 104,
71 and 53 bp, and heterozygous individuals (TC) four bands.
The Int2 conversion was genotyped by using two separate PCR reac-
tions, one that amplifies the normal gene (WT) and one that amplifies the
conversion. The size of the amplicon in each reaction is ∼418 bp.
The functionally important domains of the MR for DNA and agonist
binding, exons 3 to 9, respectively, were amplified by using the following
primers: forward 5′-TGT GCA GCA TGT TAA ATG TGC-3′, 5′-TTC
AAG GCA GGA AAG AAG TAG-3′, 5′-TGG CCT TAT CAT TTA TGG
TTT C-3′, 5′-TTC CTG GAA TGT ACT TAA ATG C-3′, 5′-CAG TCT
GGG TTT GAT AAT G-3′, 5′-CCT GGA AAT TTA CAT GTC TG-3′ or
5′-AAA GTC AGA AGG CAG AGG GAT C-3′, respectively. As reverse
primers served: 5′-AAC ACC CAC ATG AAC ATT TAC C-3′, 5′-TGC
TGT TGC ATT ACC TAT TAA C-3′, 5′-TGC AGC CTG TGA AAG GAG
AG-3′, 5′-AAA TCA TAA CGC ATA ACT CTG C-3′, 5′-TAG AAA CAG
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TGC CAG AAT G-3′, 5′-TCA CTT AGG AAC CAA GGA G-3′ or 5′-
CTT AAG GCA AAG TTC TTC TGG G-3′, respectively. The known
mutation Ser810 Leu, which was created by site-directed mutagenesis of
wild-type exon 6 of the MR, served as positive control [17]. All reac-
tions were carried out with 25 pmol of each primer in a final volume of
50 µL, containing a 4 mmol/l MgCl2 buffer, 0.2 mmol/l of each dNTP
and 1 unit of AmpliTaq Gold polymerase (PE Biosystems, Foster City,
CA, USA). The DNA was amplified for 35 cycles with denaturation
at 95◦C for 30 s, annealing at 60◦C for 30 s and extension at 72◦C
for 1 min. PCR products were investigated using a combined strat-
egy of single strand conformation polymorphism and direct sequenc-
ing to identify polymorphisms. Non-denatured and denatured (100 mM
NaOH, 0.25% bromophenol blue/xylene cyanol in formamide heated 6
min at 95◦C) PCR products were run on 12% acrylamide/piperazine-
diacrylamide (PDA) gels containing 7.25% glycerol in a two-buffer sys-
tem. Four µl of the PCR sample were loaded, separated at 12◦C, and DNA
was visualized by silver staining [18]. Sequence changes were detected
by double-band shifts on the gel. Sequence identity was verified by direct
sequencing.
Statistical analysis
All data are presented as means ± SEM. To test for statistically significant
differences, Student’s t-test was used for contniuous variables by nonpara-
metric analysis and the Wilcoxon or Kruskal–Wallace test for variables that
were not normally distributed. Linear regression analysis was performed
for the continuous parameters (birth weight and systolic/diastolic blood
pressure as related to urinary tetrahydro-aldosterone/creatinine). Standard-
ized calculations of relative risk (RR) and confidence intervals (CI) were
performed with log transformations and a normal approximation used for
the CI. For comparison of genotype distributions, the chi-square test and
Fisher’s exact test were used, taking the appearance of PE as threshold.
Comparisons for the number of mutated haplotypes were performed for
each allele contributing, for each gene, and by grouping haplotypes as
follows: no mutated haplotype [SF-1 C/C, Int2 (w)/(w)], one mutated hap-
lotype of both genes [SF-1–344C/T and Int2 (w)/(c)] and two mutated
haplotypes [SF-1 T/T and Int2 (c)/(c)]. Significance was assigned at P <
0.05. All statistical analyses were performed using either SYSTAT version
10 (SPSS Inc., Chicago, IL, USA) or GraphPad Prism version 4.01 for
Windows (GraphPad Software, San Diego, CA, USA).
Results
Patients characteristics
Basic demographic, clinical and biochemical data of the
92 pregnant women, dichotomized as to the occurrence of
PE, are reported in Table 1. There was no difference in age
and body mass index in the two groups of women. The clini-
cal status was confirmed to be uneventful within the current
and all former pregnancies in the 44 women included as
normally pregnant. PE was diagnosed in 48 women by the
presence of proteinuria and hypertension as defined above.
The birth weight of children from pre-eclamptic pregnan-
cies was >40% lower than that of children from normal
pregnancies at similar gestational weeks (Table 1). Com-
parable numbers of women with either normal pregnancy
or PE were primiparous (53 versus 57%). Twenty percent
of multiparous women experienced a first pre-eclamptic
episode, and 22% were exposed to recurrent PE. Women
with a PE in the current pregnancy had former pregnan-
cies complicated by fetal losses, premature births and low
birth weight of their children (Table 1). Antihypertensive
treatment in PE consisted of labetalol, α-methyldopa and
nifedipine.
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Fig. 2. Correlation between blood pressure and urinary tetrahydro-
aldosterone. Tetrahydro-aldosterone was measured by GC-MS in 24-
h urine of pregnant women experiencing either a normal (n = 44)
or a pre-eclamptic (n = 48) pregnancy. Systolic and diastolic blood
pressure is depicted as circles and triangles, respectively, with values
from normotensive and pre-eclamptic pregnant women closed and open,
respectively.
Correlation of tetrahydro-aldosterone secretion with
clinical patterns
Urinary tetrahydro-aldosterone excretion was significantly
reduced in pre-eclamptic women when compared to nor-
mal pregnancies (13.4 ± 1.8 µg/mmol versus 38.0 ±
9.8 µg/mmol creatinine) (Figure 2). Lower blood pressure
correlated with a higher urinary tetrahydro-aldosterone ex-
cretion (systolic r = 0.99, P < 0.04; diastolic r = 0.99,
P < 0.04) (Figure 2). High urinary tetrahydro-aldosterone
excretion was found in the presence of higher birth weights
in normal pregnancies as compared to the lower tetrahydro-
aldosterone excretion and birth weights in PE (38.0 ± 9.8
versus 13.4 ± 1.8 µg/mmol creatinine;P< 0.05 and 3286 ±
98 g versus 1774 ± 179 g; P < 0.05).
Genotype and haplotype analysis of MR and CYP11B2
gene polymorphisms (Figure 1)
A PCR-based screening for mutations in the DNA and
steroid-binding domanins of the MR was performed, and
no amindo acid-changing mutation leading to structural or
functional changes was identified.
The CYP11B2 genotype distribution within the popula-
tion of the pregnant women and the controls studied were
in Hardy–Weinberg equilibrium. Normotensive pregnan-
cies more likely took place in the presence of homozy-
gosity for Int2 (c)/(c) (P = 0.0046), but less frequently
with Int2 (w)/(w) (P = 0.015). Homozygosity for SF-1
T/T was associated with reduced occurrence of hyperten-
sive pregnancies (P = 0.016, Figure 3), yet heterozygosity
did not protect from PE (P = 0.012). Combining alleles
associated with high aldosterone-to-renin ratios indicated
an increased frequency of these alleles in normotensive
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Fig. 3. Allelic distribution of SF-1 T and Int2 (c) haplotypes of CYP11B2. Percentage of patients by allelic distribution of SF-1 T and Int2 (c) haplotypes
of CYP11B2 according to pregnancy outcome. Open bars indicate healthy normotensive males, grey bars indicate normal pregnancies and black bars
PE.
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Fig. 4. Percentage of patients by number of SF-1 T and Int2 (c) haplotypes
of CYP11B2 according to pregnancy outcome. Grey bars indicate normal
pregnancies and black bars PE.
when compared to pre-eclamptic pregnancies (2.6 ± 0.3
versus 1.9 ± 0.2 alleles; P = 0.023). So far, these results
point towards a relationship between pregnancy outcome
and the number of mutant haplotypes. The presence of
two, yet not one, mutant haplotypes for each gene locus
was highly significantly linked to uneventful pregnancies
(P < 0.001, Figure 4). The relative risk of developing PE
was not reduced with one mutant haplotype, but with two
(compared to no and one mutant haplotype RR 0.16; CI
0.05–0.54).
Discussion
This study shows an association of maternal blood pres-
sure and fetal birth weight with aldosterone availability.
As proposed, in normal pregnancies a high aldosterone
production, determined via the measurement of urinary
tetrahydro-aldosterone excretion, the most sensitive marker
of circadian aldosterone production, was related to low ma-
ternal blood pressure levels [19]. Confirming our hypoth-
esis, the number of high aldosterone-to-renin ratio alleles
was increased in normal pregnancies. The absence of a
high aldosterone-to-renin ratio allele of intron 2 was asso-
ciated with an augmented frequency of PE. Furthermore,
the presence of both mutants significantly favoured normal
pregnancies.
The clarification of mechanisms of PE and hyperten-
sion in pregnancy is of practical relevance for multiple rea-
sons with preventing the disease being the most important
one [20–25]. If high aldosterone levels and the increased
circulating plasma volume found in normal pregnancies
represent a physiological adaptation crucial to support an
adequate circulating fluid volume in pregnancy, two obser-
vations should be possible: first, a phenotypical adaptation
in response to the aldosterone available, and second, mech-
anisms within the mineralocorticoid system either leading
to or mimicking high aldosterone availability should prove
beneficial to avoid PE [4–9,26].
If the primary impact of sufficient aldosterone availabil-
ity would be to benefit pregnancy by avoiding PE, a genetic
predisposition to produce high quantities of aldosterone or
to appropriately respond to a given aldosterone concentra-
tion via the MR would be reasonable. Such a predisposition
has been recognized by two gene loci of Mendelian forms
of the CYP11B2 gene, the promoter SF-1 single nucleotide
polymorphism -344C/T and a conversion in intron 2, which
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are variably linked to arterial mineralocorticoid hyperten-
sion with increased aldosterone-to-renin ratios in the non-
pregnant population [12]. With these findings we stay in
line with our initial finding of a compromised aldosterone
synthesis being associated with PE [11].
In our study, the most pronounced differences between
normal pregnancies and PE could be observed, if either an
increased number of high ARR alleles or homozygosity for
the mutant form were present. The RR to develop PE was
reduced by >80%, if women were homozygous for both
mutant alleles. Thus, combinations of activating polymor-
phisms seem to add to an uneventful pregnancy outcome,
most likely due to an amplified aldosterone production as
has been demonstrated during postural changes, when the
maximal aldosterone response was found in subjects with
two mutant haplotypes [12]. This observation is in line
with our results and supports the view that variations in
CYP11B2 may well lead to an intermediate phenotype of
aldosterone excess supporting arterial hypertension in non-
pregnant subjects and normotension during pregnancy due
to an improved utero-placental perfusion.
One of these polymorphisms, the SF-1–344C/T conver-
sion, had been studied in a pre-eclamptic population from
Turkey with a lack of association [27]. A direct compar-
ison of these data with our current findings is limited by
the missing information on primiparity, which was high in
our study group, and the ethnic divergence between the
study groups. Also, we investigated a group of pregnant
women as controls without any abnormalities in their for-
mer pregnancy history, which may have resulted in a bias
towards genotypes of the CYP11B2 with a high aldosterone
production. Furthermore, PE appears to be a multifactorial
disease with each factor potentially contributing to a dif-
ferent extent, even more in a genetically divergent context.
Interestingly, the low expression of high aldosterone-to-
renin ratio variants in PE resembled the pattern seen in the
healthy, normotensive, non-pregnant subjects in our and
earlier studies [12]. This observation does support the no-
tion that CYP11B2 variants, which predispose women to
PE, are rather frequent and any additional contributing fac-
tor could easily expose women to the risk of developing
PE.
This study supports the assumption that an uncompro-
mised aldosterone production is importantly contributing
to an uneventful pregnancy outcome. If aldosterone pro-
duction is diminished due to a polymorphism within the
CYP11B2 gene, the reduced aldosterone availability in the
presence of increasing concentrations of the partial aldos-
terone antagonist progesterone throughout gestation might
reduce the compensatory potential for shifts in circulating
volume warranting the genotypes discussed here with a high
capacity to produce aldosterone [11]. Our current observa-
tions well support the concept of a genetic susceptibility
of PE as has been repetitively demonstrated in family and
twin studies, though stable environmental factors must also
be considered in recurrent PE and have not been addressed
here [28–30].
The exact mechanisms determining the magnitude of
aldosterone secretion in the presence of the CYP11B2 vari-
ants have not yet been elucidated [31]. Adrenal release of
aldosterone is reduced in hypoxia as shown by Raff and
Kohandarvish [32] in vitro and by Lawrence et al. [32,33].
Thus, one might speculate that during established PE factors
such as adrenal hypoxemia further contribute to a dimin-
ished aldosterone release.
Earlier, we ruled out aldosterone levels to be decreased
due to an excess of alternate mineralocorticoid-like steroid
hormones [11]. Yet, aldosterone concentrations might be
affected by an altered activity of the MR by either gain-
or loss-of-function mutations within functionally relevant
regions of the MR gene [13,17,34]. Our present data do
support the assumption that structural or functional muta-
tions of the MR are extremely rare and will not have to
be judged as a contributing major factor to explain the fre-
quently occurring PE, a finding supporting observations in
very small subsets of pre-eclamptic patients by other groups
[35,36].
The present investigation revealed a close relationship
between aldosterone availability, gestational maternal blood
pressure and fetal birth weight. High aldosterone-to-renin
ratio variants of the CYP11B2, which provide for an in-
creased aldosterone availability, were associated with a
lower frequency of pre-eclamptic pregnancies. Most strik-
ingly, double homozygosity for both high aldosterone-to-
renin ratio variants, predicted a significantly reduced risk
of developing PE. Though the exact regulatory events for
CYP11B2 in pregnancy still have to be elucidated more in
detail, this observation is of practical importance since it
might help to define subgroups of patients with an altered
chance to develop pregnancies complicated by PE. Thus,
women could be given a tailored follow-up throughout their
pregnancies according to their CYP11B2 genotype in ad-
dition to further risk predictors. These results should be
verified in a larger cohort also including women with an
intermediate phenotype.
Acknowledgements. This work has been supported in part by a grant
for scientific research from the Swiss National Science Foundation (No.
3200B0-113902/1 to M.M.) and a Marie-Heim Vo¨glein grant (PMPDB-
106128 to G.E.).
Conflict of interest statement. None to be declared.
(See related article by M. D. Lindheimer and P. August. Aldosterone,
maternal volume status and healthy pregnancies: a cycle of differing views.
Nephrol Dial Transplant 2009; 24: 1712–1714.)
References
1. Broughton-Pipkin F. Risk factors for preeclampsia. N Engl J Med
2001; 344: 925–926
2. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal
risk of ischaemic heart disease: a retrospective cohort study of 129,290
births. Lancet 2001; 357: 2002–2006
3. Irgens HU, Reisaeter L, Irgens LM et al. Long term mortality of
mothers and fathers after pre-eclampsia: population based cohort
study. BMJ 2001; 323: 1213–1217
4. Bauknecht H, Vecsei P, Endres H et al. Urinary free 18-
hydroxycorticosterone, plasma aldosterone, and urinary aldosterone
metabolites in normal pregnancy. Am J Obstet Gynecol 1982; 144:
28–34
Mineralocorticoid system and pregnancy 1875
5. Brown MA, Sinosich MJ, Saunders DM et al. Potassium regulation
and progesterone-aldosterone interrelationships in human pregnancy:
a prospective study. Am J Obstet Gynecol 1986; 155: 349–353
6. Wacker J, Piel P, Lewicka S et al. Increased aldosterone-18-
glucuronide/tetrahydroaldosterone ratios in pregnancy. Endocr Res
1995; 21: 197–202
7. McCance DR, McKnight JA, Traub AI et al. Plasma atrial natriuretic
factor levels during normal pregnancy and pregnancy complicated by
diabetes mellitus and hypertension. J Hum Hypertens 1990; 4: 31–35
8. Gallery ED, Brown MA. Control of sodium excretion in human preg-
nancy. Am J Kidney Dis 1987; 9: 290–295
9. Mulrow PJ, Schneider G. Aldosterone regulation in the maternal and
fetal rat in pregnancy. Perspect Nephrol Hypertens 1976; 5: 229–237
10. Nolten WE, Lindheimer MD, Oparil S et al. Desoxycorticosterone in
normal pregnancy: I. Sequential studies of the secretory patterns of
desoxycorticosterone, aldosterone, and cortisol. Am J Obstet Gynecol
1978; 132: 414–420
11. Shojaati K, Causevic M, Kadereit B et al. Evidence for compro-
mised aldosterone synthase enzyme activity in preeclampsia. Kidney
Int 2004; 66: 2322–2328
12. Nicod J, Bruhin D, Auer L et al. A biallelic gene polymorphism of
CYP11B2 predicts increased aldosterone to renin ratio in selected
hypertensive patients. J Clin Endocrinol Metab 2003; 88: 2495–
2500
13. Geller DS, Rodriguez-Soriano J, Vallo Boado A et al. Mutations in
the mineralocorticoid receptor gene cause autosomal dominant pseu-
dohypoaldosteronism type I. Nat Genet 1998; 19: 279–281
14. Higgins JR, de Swiet M. Blood-pressure measurement and classifica-
tion in pregnancy. Lancet 2001; 357: 131–135
15. Shackleton CH. Mass spectrometry in the diagnosis of steroid-related
disorders and in hypertension research. J Steroid Biochem Mol Biol
1993; 45: 127–140
16. Davies E, Holloway CD, Ingram MC et al. An influence of variation in
the aldosterone synthase gene (CYP11B2) on corticosteroid responses
to ACTH in normal human subjects. Clin Endocrinol (Oxf) 2001; 54:
813–817
17. Geller DS, Farhi A, Pinkerton N et al. Activating mineralocorticoid
receptor mutation in hypertension exacerbated by pregnancy. Science
2000; 289: 119–123
18. Smolenicka Z, Bach E, Schaer A et al. A new polymorphic restriction
site in the human 11 beta-hydroxysteroid dehydrogenase type 2 gene.
J Clin Endocrinol Metab 1998; 83: 1814–1817
19. Abdelhamid S, Blomer R, Hommel G et al. Urinary tetrahydroaldos-
terone as a screening method for primary aldosteronism: a comparative
study. Am J Hypertens 2003; 16: 522–530
20. Luft FC. Molecular genetics of human hypertension. Curr Opin
Nephrol Hypertens 2000; 9: 259–266
21. Curnow KM, Pham T, August P. The L10F mutation of angiotensino-
gen is rare in pre-eclampsia. J Hypertens 2000; 18: 173–178
22. Arngrimsson R, Purandare S, Connor M et al. Angiotensinogen: a
candidate gene involved in preeclampsia? Nat Genet 1993; 4: 114–
115
23. Harrison GA, Humphrey KE, Jones N et al. A genomewide link-
age study of preeclampsia/eclampsia reveals evidence for a candidate
region on 4q. Am J Hum Genet 1997; 60: 1158–1167
24. Pridjian G, Puschett JB. Preeclampsia: Part 1. Clinical and pathophys-
iologic considerations. Obstet Gynecol Surv 2002; 57: 598–618
25. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia.
Lancet 2001; 357: 53–6
26. Lindheimer MD, Katz AI. Renal physiology and disease in pregnancy.
In: Seldin DW, Giebisch G (eds). The Kidney: Physiology and Patho-
physiology, 2nd edn. New York: Raven Press, 1992, 3371–3433.
27. Percin FE, Cetin M, Pinarbasi E et al. Lack of association between the
CYP11B2 gene polymorphism and preeclampsia, eclampsia, and the
HELLP syndrome in Turkish women. Eur J Obstet Gynecol Reprod
Biol 2006; 127: 213–217
28. Nilsson E, Salonen Ros H, Cnattingius S, Lichtenstein P. The im-
portance of genetic and environmental effects for pre-eclampsia and
gestational hypertension: a family study. BJOG 2004; 111: 200–
206
29. Salonen Ros H, Lichtenstein P, Lipworth L et al. Genetic effects on
the liability of developing pre-eclampsia and gestational hypertension.
Am J Med Genet 2000; 91: 256–260
30. Thornton JG, Macdonald AM. Twin mothers, pregnancy hypertension
and pre-eclampsia. Br J Obstet Gynaecol 1999; 106: 570–575
31. Lim PO, Macdonald TM, Holloway C et al. Variation at the aldos-
terone synthase (CYP11B2) locus contributes to hypertension in sub-
jects with a raised aldosterone-to-renin ratio. J Clin Endocrinol Metab
2002; 87: 4398–4402
32. Raff H, Kohandarvish S. The effect of oxygen on aldosterone release
from bovine adrenocortical cells in vitro: PO2 versus steroidogenesis.
Endocrinology 1990; 127: 682–687
33. Lawrence DL, Skatrud JB, Shenker Y. Effect of hypoxia on atrial
natriuretic factor and aldosterone regulation in humans. Am J Physiol
1990; 258: E243–E248
34. Pearce D, Bhargava A, Cole TJ. Aldosterone: its receptor, target genes,
and actions. Vitam Horm 2003; 66: 29–76
35. Schmider-Ross A, Wirsing M, Buscher U et al. Analysis of the
S810L point mutation of the mineralocorticoid receptor in patients
with pregnancy-induced hypertension. Hypertens Pregnancy 2004;
23: 113–119
36. Tempfer CB, Jirecek S, Riener EK et al. Polymorphisms of throm-
bophilic and vasoactive genes and severe preeclampsia: a pilot study.
J Soc Gynecol Investig 2004; 11: 227–231
Received for publication: 26.9.08; Accepted in revised form: 19.12.08
